Can matching treatment to genetic risk beat relapsed childhood leukemia?

NCT ID NCT05827549

Recruiting now ⭐️ CURE ⭐️ Sponsor: Ho Joon Im Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is testing whether a treatment plan tailored to each child's genetic risk can improve outcomes for relapsed acute lymphoblastic leukemia. Children and young adults up to age 22 whose leukemia has returned in the bone marrow receive a combination of chemotherapy drugs, and those at high risk also get the immunotherapy blinatumomab before a stem cell transplant. The goal is to see if this risk-based approach leads to better long-term survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of chemotherapy drugs (prednisolone, vincristine, L-asparaginase, idarubicin, ifosfamide, etoposide, methotrexate, cytarabine) and the immunotherapy blinatumomab
What this could lead to: If successful, this approach could improve cure rates for children whose leukemia has returned, by matching treatment intensity to each child's specific risk.
What could go wrong: This is a Phase 2 trial, so the strategy is still experimental. The chemotherapy and immunotherapy carry significant side effects, and not all children may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma T-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOID LEUKEMIA

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Chonnam National University Hwasun Hospital
RECRUITING

Hwasun, 58128, South Korea
Chungnam National University Hospital
NOT_YET_RECRUITING

Daejeon, 35015, South Korea
Jeju National University Hospital
NOT_YET_RECRUITING

Jeju City, 63241, South Korea
Kyungpook National University Chilgok Hospital
NOT_YET_RECRUITING

Daegu, 41404, South Korea
Pusan National University Yangsan Hospital
RECRUITING

Yangsan, 50612, South Korea
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Seoul saint Mary's Hospital
RECRUITING

Seoul, 06591, South Korea
Severance Hospital
RECRUITING

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.